BioSpace News Archive

Eurofins Genomics U.S. announces that, together with its subsidiary BlueHeron Biotechnology, it has launched a series of SARS-CoV-2 plasmid DNA controls that can be used to verify the presence of the SARS-CoV-2 virus.

GENYOUth, a nonprofit organization dedicated to creating healthier school communities, today announced the appointment of Maureen Bausch as the organization’s Chief Development Officer – GENYOUth COVID-19 Emergency School Nutrition Fund.

Vayyar collaborates with Israel’s Ministry of Defense to utilize a touchless remote monitoring system that detects and monitors vital signs that can indicate early-stage COVID-19 symptoms

Sino Biological, Inc. today announced a co-development agreement with Nanommune Inc., an Irvine, California based biotechnology company specializing in the development and application of multiplex array technology. Under the terms of the agreement, the two companies will jointly develop coronavirus antigen array products for serological studies of COVID-19 and other infectious diseases.

Getinge introduces one of its latest connectivity solutions for acute care products.

iSpecimen today announced it is deeply engaged in the battle against COVID-19, supporting researchers who are working on urgently needed vaccines, tests and treatments for the deadly viral disease.

Is there any specific drug to fight against COVID-19? When can we get access to the specific drug? These two questions are hard to answer for now. Developing the specific drug is quite tough. It is not practical when R&D works of new drugs usually takes too long and costs too much.

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific antibodies (mAb2™), today announces the publication in Clinical Cancer Research of preclinical data highlighting the potential novel mechanism of action of its wholly-owned lead clinical asset FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI’s patented Pressure Cycling Technology

Direct Relief today announced a donation from AstraZeneca of 3 million surgical masks for US healthcare workers battling Covid-19.